High-Dose Clopidogrel in Patients with High Residual Reactivity: Results from the GRAVITAS Trial

Summary

Doubling the dose of clopidogrel in patients with high residual platelet activity after percutaneous intervention has no significant effect on cardiovascular outcomes, according to the neutral results of the Gauging Responsiveness with A VerifyNow Assay—Impact on Thrombosis And Safety [GRAVITAS; NCT00645918] trial.

  • Interventional Techniques & Devices Clinical Trials
  • Thrombotic Disorders
View Full Text
Back to top

Tools

View Full Page PDF
Citation Tools
Email
High-Dose Clopidogrel in Patients with High Residual Reactivity: Results from the GRAVITAS Trial
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Interventional Techniques & Devices Clinical Trials
Thrombotic Disorders